Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

26 Apr 2018

Abstract excerpt

Abstract Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have also been proposed for treatment of mRCC with encouraging results. A better understanding of the activity of immune cells in mRCC, the immunomodulatory effects of TKIs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to HER2/EGFR in Cancer Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29700053
DOI: 10.1158/2326-6066.cir-17-0594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwayPMID 29700053Read ↗

Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunitySemantic proximity Read ↗

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studySemantic proximity Read ↗

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsSemantic proximity Read ↗

The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)Semantic proximity Read ↗

Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapySemantic proximity Read ↗

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.Semantic proximity Read ↗

PIKfyve controls dendritic cell function and tumor immunitySemantic proximity Read ↗

Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical ImplicationsSemantic proximity Read ↗

An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasionSemantic proximity Read ↗

The tumor necrosis superfamily member 4-1BBL expressed by tumor cells prevents exhaustion of CD8 T cells in a humanized mouse model of papillary renal cell carcinomaSemantic proximity Read ↗

Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.